ADC Therapeutics SA
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $ADCT in the last 7 days.
No SEC Form 4 filings for $ADCT in the last 30 days.
See all $ADCT insider activity →ADC Therapeutics raised $86.6M via private placement, amended its Blue Owl loan to prepay $70M and retain $50M, and revised its HCR Royalty deal to add a buyout option and reduce debt capacity. The moves aim to improve liquidity and flexibility.
ADC Therapeutics SA (ADCT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ADC Therapeutics Announces Comprehensive Strategic Financial Restructuring Marking Key Capital Structure Improvements $86.6 Million Private Placement announced, with participation from new and existing investors, extending expected cash runway into 2029 HealthCare Ro
ADC Therapeutics (ADCT) raised $86.6M via private placement, selling shares and warrants. It restructured debt, extending cash runway to 2029. Q3 ZYNLONTA revenue was $21M, with $189.2M cash as of September 30, 2026. Proceeds will fund pipeline studies, including Phase 3 trials.
Recent ADCT coverage spans earnings, corporate actions and market movers.
The capital raise improves liquidity and removes covenant constraints, which may support the stock price.
Balance‑sheet strengthening and new equity financing should support the stock, though dilution may temper upside.
The financing adds cash but dilutes existing shareholders, likely creating modest upside pressure.
Short-term pressure from FDA concerns may weigh on price, but improved cash position and reduced loss provide upside potential.
Improved financial metrics and cost reductions may support short-term price stability, but ongoing regulatory concerns add downside risk.
AlphAI scores every news story that mentions ADCT with an AI model for sentiment and relevance, and aggregates insider trades from ADC Therapeutics SA's SEC EDGAR Form 4 filings. Figures refresh continuously.
ADC Therapeutics raised $86.6M via private placement, amended its Blue Owl loan to prepay $70M and retain $50M, and revised its HCR Royalty deal to add a buyout option and reduce debt capacity. The moves aim to improve liquidity and flexibility.
2 min readADC Therapeutics SA (ADCT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ADC Therapeutics Announces Comprehensive Strategic Financial Restructuring Marking Key Capital Structure Improvements $86.6 Million Private Placement announced, with participation from new and existing investors, extending expected cash runway into 2029 HealthCare Ro
2 min readADC Therapeutics (ADCT) raised $86.6M via private placement, selling shares and warrants. It restructured debt, extending cash runway to 2029. Q3 ZYNLONTA revenue was $21M, with $189.2M cash as of September 30, 2026. Proceeds will fund pipeline studies, including Phase 3 trials.
2 min readADC Therapeutics (ADCT) reported Q2 earnings with steady ZYNLONTA revenue at $18.6M and reduced net loss to $16.6M. The FDA raised safety concerns about a combination trial, creating regulatory uncertainty. The company cut operating expenses by 29% and has cash to last into 2028. Short interest is at 5.70% of the float.
3 min readADC Therapeutics (ADCT) reported Q2 2026 net product revenue of $18.6M, up from $18.1M YoY. Net loss narrowed to $16.6M ($0.11 per share) from $56.6M YoY. Cash reserves totaled $219.1M, expected to last into 2028. The company reduced operating expenses by 22% YoY and cut 17% of its workforce. FDA raised concerns about the LOTIS-5 trial, prompting ADCT to assess regulatory paths for ZYNLONTA. Management plans to seek breakthrough designation for ZYNLONTA plus glofitamab combination therapy.
3 min readADC Therapeutics SA (ADCT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ADC Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Updates Second quarter 2026 net product revenue of $18.6 million; cash and cash equivalents of $219.1 million as of June 30, 2026 LOTIS-7, LOTIS-5 and MZL IIT data submitted for p
6 min readADC Therapeutics (NYSE: ADCT) reported Q2 2026 net product revenue of $18.6M (vs. $18.1M in Q2 2025) and cash and cash equivalents of $219.1M as of June 30, 2026. The FDA held a pre-sBLA meeting on LOTIS-5; the company is assessing the regulatory path. LOTIS-7 enrollment is complete and data were submitted to ASH.
6 min readThe Russell 2000 stayed near 3,000 with little movement, while seven small-cap stocks gained at least 28% in four sessions. The article cites July surges for Orthofix (OFIX) on CMS reimbursement reversal, REGENXBIO (RGNX) on FDA resubmission alignment and AbbVie milestone, Verastem (VSTM) on short-squeeze setup, ADC Therapeutics (ADCT) rebound, Sable Offshore (SOC) refinancing, Rapid7 (RPD) takeover speculation, and Crinetics (CRNX) surge toward an offer price.
7 min readADC Therapeutics SA (ADCT) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001771910 0001771910 2026-06-30 2026-06-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor
3 min readADC Therapeutics (NYSE: ADCT) said enrollment is complete in its LOTIS-7 Phase 1b trial of ZYNLONTA (loncastuximab tesirine-lpyl) plus glofitamab (COLUMVI) for relapsed/refractory DLBCL. 100 patients were dosed at 150 µg/kg; full data are expected in Q4 2026. Prior reported ORR was 89.8% with 77.6% CR.
3 min read
